Sotyktu (deucravacitinib) / BMS - LARVOL DELTA

Transcriptomic Analysis of TYK2 Inhibition as a Therapeutic Target in Lichen Planopilaris (AAD 2026) - "Deucravacitinib is an oral selective inhibitor of tyrosine kinase 2 (TYK2)...These results suggest TYK2 inhibition may target the key inflammatory pathways implicated in LPP. # - equal contribution * - corresponding author"

Omic analysis • Alopecia • Fibrosis • Immunology • Inflammation • Lichen Planus • CCL19 • COL1A1 • COL1A2 • COL3A1 • COL5A1 • CXCL13 • CXCL9 • IFI27 • MMP1 • MMP13 • MMP9 • MX1 • TYK2

Humility is lacking in self-reported treatment adherence among psoriasis patients (AAD 2026) - "Despite objective differences, patients in high and low adherence groups reported they consistently took deucravacitinib as prescribed. There is a lack of humility in self-report and limited discriminative validity of common adherence prompts. Reframing questions, normalizing lapses, and eliciting specific behaviors may improve the accuracy and clinical usefulness of patient self-reports on adherence."

Adherence • Clinical • Dermatology • Immunology • Psoriasis

Risankizumab vs Deucravacitinib in Adults With Moderate Plaque Psoriasis: Week 16 Subgroup Results From the IMMpactful Study (AAD 2026) - P4 | "Safety data were generally consistent with known profiles of both treatments. This analysis suggests that risankizumab provides greater clinical improvements vs deucravacitinib in patients with moderate plaque psoriasis across patient subgroups with safety outcomes consistent with the known safety profile of risankizumab."

Clinical • Dermatology • Immunology • Psoriasis • TYK2

Efficacy and safety of deucravacitinib vs placebo in patients with active psoriatic arthritis by concomitant methotrexate use: a pooled analysis of pivotal phase 3 studies (AAD 2026) - P3 | "Deucravacitinib was superior to placebo in improving clinical responses, controlling disease activity, reducing extraarticular manifestations of PsA, and enhancing functional ability, and it was well tolerated regardless of concomitant methotrexate use."

P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TYK2

Deucravacitinib in the Treatment of Pityriasis Rubra Pilaris: A Phase 2 Clinical Trial (AAD 2026) - "Deucravacitinib demonstrated significant clinical improvement and exhibited a favorable safety profile. # - equal contribution * - corresponding author"

Clinical • P2 data • Dermatopathology • Inflammation • IL12A • IL23A • TYK2

Shifting Role of Oral Therapies in Psoriasis: Unmet Needs and Perspectives on Current and Emerging Therapies, and Evolving Treatment Sequencing Among Dermatologists. (AAD 2026) - " Deucravacitinib gained first-line traction, with dermatologists increasingly delaying biologic initiation...Pipeline interest shifted year-over-year: oral IL-17 and aIL-23R mechanisms remained most valued (>83%), but icotrokinra (oral aIL-23R) emerged as the leading candidate, with aIL-23R awareness surpassing IL-17 agents and >60% of dermatologists favoring icotrokinra for first-line use, while TYK2 inhibitors (envudeucitinib, zasocitinib) were increasingly viewed as later-line options... Dermatologists report an expanding role for oral therapies in PsO. Broader availability of effective oral agents is expected to further delay biologic initiation, representing a paradigm shift in PsO management."

Dermatology • Immunology • Psoriasis • TYK2

Superior Modulation of the IL-23–IL-17 Axis by Risankizumab Compared With Deucravacitinib at Week 16: Serum Biomarker Analysis From IMMpactful, a Phase 4, Randomized, Open-Label, Head-to-Head Study in Moderate Plaque Psoriasis (AAD 2026) - P4 | "The greater effects on disease-associated cytokines observed with risankizumab provide molecular evidence to support the observed clinical superiority over deucravacitinib. Further investigation, especially within psoriatic lesions, is warranted to better understand the molecular mechanisms involved."

Biomarker • Clinical • Head-to-Head • P4 data • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • CRP • IL17A • IL17C • IL22 • IL23A • TYK2

Robust icotrokinra systemic and skin pharmacodynamic effects versus deucravacitinib in patients with moderate-to-severe plaque psoriasis: results from phase 3, ICONIC-ADVANCE-1 study (AAD 2026) - "Icotrokinra significantly reduced systemic and skin PsO biomarkers to a greater extent than deucravacitinib. These pharmacodynamic findings align with the superior skin clearance achieved with icotrokinra, supporting its clinical efficacy through robust inhibition of IL-23 signaling and PsO disease activity."

Clinical • P3 data • PK/PD data • Dermatology • Immunology • Psoriasis • IL17A • IL17C • IL22 • IL23A

Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16 (AAD 2026) - P4 | "Conclusions Patients with moderate plaque psoriasis treated with RZB achieved higher skin clearance than those treated with DEU. Higher skin clearance resulted in increased symptom relief and better QoL."

Clinical • HEOR • Dermatology • Immunology • Psoriasis • TYK2

Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials (AAD 2026) - P3 | "Introduction: Among adults with moderate-to-severe plaque psoriasis in ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), the targeted oral peptide icotrokinra (ICO) demonstrated significantly higher rates of skin clearance vs placebo (PBO) at Week (W)16 and vs deucravacitinib (Deucra) at W16&W24, with adverse event (AE) rates similar to PBO and numerically lower than Deucra.1 Here, ICO findings through W52 of ICONIC-ADVANCE 1&2 are reported. ICO provided robust and durable skin response rates through 1 year of treatment; skin clearance rates increased in Deucra-randomized pts after transitioning to ICO. No ICO safety signals were identified."

Clinical • P3 data • Dermatology • Immunology • Psoriasis

The impact of deucravacitinib on health-related quality of life and fatigue in patients with psoriatic arthritis: pooled analysis of phase 3 trials in patients with active psoriatic arthritis (AAD 2026) - P3 | "Deucravacitinib significantly improved symptoms, functioning, HRQoL, and fatigue compared with placebo in patients with active PsA in a pooled analysis of phase 3 trials."

HEOR • P3 data • Retrospective data • Fatigue • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis (AAD 2026) - "Over several years, he failed multiple therapies including topical corticosteroids, oral prednisone, and systemic immunosuppressants (methotrexate, cyclosporine, mycophenolate). Biologic agents such as dupilumab, ixekizumab, and apremilast were also ineffective...Initial risankizumab monotherapy (IL-23 inhibitor) reduced BSA from 65% to 20%. Due to incomplete clearance, deucravacitinib (TYK2 inhibitor) was added, resulting in further improvement to 4% BSA over 16 months. The combination was well tolerated with no adverse effects. This case highlights the potential efficacy of dual IL-23 and TYK2 inhibition and supports individualized, flexible treatment strategies for refractory psoriasis."

Monotherapy • Atopic Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis • IL17A • IL23A • IL4 • TYK2

Efficacy and safety of deucravacitinib in genital psoriasis: data from a phase 4 study (AAD 2026) - P4 | "Improvements in sPGA-G 0/1, sPGA 0/1, and CFB in GenPs INRS score were observed with deucravacitinib. These are the first data showing deucravacitinib efficacy in GenPs and provide additional evidence for deucravacitinib treatment of psoriasis in special areas."

Clinical • P4 data • Cardiovascular • Dermatology • Hypertension • Immunology • Infectious Disease • Psoriasis • TYK2

Advances in the use of Janus kinase inhibitors. (PubMed, Curr Opin Rheumatol) - "Increased use of JAKi in the management of IMIDs is ongoing and will accelerate if the positive results noted in trials for lupus, inflammatory myopathies, and psoriatic arthritis result in regulatory approval. The article highlighted in this review provide an update on the progress being made in newer rheumatic disease indications as well as efforts to better understand the adverse event profile for patients on treatment."

Journal • Ankylosing Spondylitis • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Myositis • Oncology • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Venous Thromboembolism • TYK2

Improvement of neurological symptoms and associated biomarkers with deucravacitinib in patients with systemic lupus erythematosus in the phase 2 PAISLEY SLE trial (EULAR 2026) - No abstract available

Biomarker • Clinical • P2 data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Efficacy and safety of deucravacitinib through week 52 in patients with active psoriatic arthritis: impact of concomitant methotrexate use in a pooled analysis of the pivotal phase 3 POETYK PsA trials (EULAR 2026) - No abstract available

P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

The COMBo study: a randomized trial of deucravacitinib-TNF inhibitor combination therapy versus TNF inhibitor monotherapy in difficult-to-control psoriatic disease (EULAR 2026) - No abstract available

Clinical • Combination therapy • Monotherapy • Immunology

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: pooled safety and adverse events of special interest in the phase 3 POETYK PsA-1 and PsA-2 trials (EULAR 2026) - No abstract available

Adverse events • Clinical • P3 data • TYK2

Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis). (PubMed, Dermatol Ther (Heidelb)) - "Deucravacitinib demonstrated clinical effectiveness and a favorable safety profile in real-world practice, including excellent scalp clearance rates, confirming its therapeutic value even in patients with difficult-to-treat areas."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Zasocitinib (TAK-279), an investigational oral, allosteric, highly selective and potent TYK2 inhibitor preserves anti-inflammatory IL-10 signalling in vitro (ECCO-IBD 2026) - "This study assessed the effect of zasocitinib, deucravacitinib (TYK2 inhibitor) and upadacitinib (JAK1 inhibitor) treatment on IL-10 signalling. Given the immunosuppressive role of IL-10 in IBD, these observations support the ongoing investigation of zasocitinib as a potential therapeutic for patients. Ongoing clinical trials will further evaluate efficacy and safety of zasocitinib in patients with IMIDs, including IBD."

Preclinical • Inflammatory Bowel Disease • IL10 • IL12A • IL1B • IL23A • IL6 • TNFA • TYK2

Wong-type dermatomyositis with NXP-2 antibodies (AAD 2026) - "Patient History: A 52-year-old female with psoriasis on adalimumab presented with a subacute photosensitive, pruritic rash on her chest, back, face, and extremities; weakness; joint stiffness; and dyspnea...Treatment: She initially began hydroxychloroquine 400mg and prednisone 10mg daily with rheumatology...Methotrexate 20mg weekly with prednisone 10mg showed no improvement, deucravacitinib 6mg daily improved skin and subjective weakness...WDM, debated as either a DM subtype or a rare manifestation, exhibits overlapping features of the papulosquamous disorder pityriasis rubra pilaris, characterized by hyperkeratotic follicular papules[1,3,4]. High-risk features, including age >40 at onset and NXP-2 antibodies, warrant enhanced malignancy surveillance[2]."

Dermatomyositis • Immunology • Myositis • Psoriasis • Pulmonary Disease • MUC16

PRAC adopted an extension of indication for SOTYKTU (deucravacitinib) to treat active psoriatic arthritis in adults, alone or with conventional synthetic DMARDs, in patients with inadequate response or intolerance to prior therapy. The SmPC and Package Leaflet were updated accordingly. (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 12 – 15 Jan 2026: [AI generated summary]

PRAC • Immunology • Psoriatic Arthritis

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL-23 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time-point being considered. At 16 weeks, for PSSI-100, ixekizumab 150 mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16 weeks, for Sc-PGA 0/1 bimekizumab 320 mg every 4 weeks ranked highest; at 8 weeks, for PSSI-100 ixekizumab 80 mg every 2 weeks ranked highest; at 8 weeks, for Sc-PGA 0/1 secukinumab 300 mg at weeks 1, 2, 3 and then every 4 weeks ranked highest. Small-molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision-making."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology. (PubMed, Nat Commun) - "We use cryptic exon detection as a proxy for TDP-43 mislocalization and demonstrate that FDA-approved JAK inhibitors baricitinib and ruxolitinib, which block interferon signaling, show protective effects only in brains with elevated cryptic exon expression. A CRISPR screen reveals TYK2 as a top hit, and TYK2 knockdown and the selective TYK2 inhibitor deucravacitinib rescue cdsRNA-induced toxicity. We find parallel neuroinflammatory mechanisms, dependent on TYK2 - a potential disease-modifying target - for TDP-43-associated Alzheimer's disease and C9ORF72-ALS."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • TARDBP • TYK2